P81 Antibody to Cardiotonic Steroid Reduces Blood Pressure and Vascular Fibrosis in Preeclampsia

NI Agalakova1, VA Reznik1, OV Nadei1, IA Ershov1, OS Rassokha1, ML Vasyutina2, MM Galagudza2, AY Bagrov1,3,*

1Department of Obstetrics and Gynecology, School of Pediatric Medicine
2Institute of Experimental Medicine, Almazov National Medical Research Centre
3Sechenov Institute of Evolutionary Physiology and Biochemistry, St. Petersburg, Russia

ABSTRACT

Background: Previous studies implicated cardiotonic steroids, including Na/K-ATPase inhibitor marinobufagenin (MBG), in the pathogenesis of preeclampsia (PE). We demonstrated that MBG induces fibrosis via mechanism involving inhibition of Fli1, a nuclear transcription factor and a negative regulator of collagen-1 synthesis.

Objectives and Methods: We hypothesized that PE blockade of increased MBG with antibody would lessen the fibrosis of umbilical arteries and lower the blood pressure in rats with PE. We tested 36 pregnant Sprague-Dawley rats in which 12 were made hypertensive by 1.8% Na supplementation (days 6–19 of gestation), 12 pregnant rats served controls. At day 19, PE rats received one intraperitoneal injection of polyclonal anti-MBG-4 antibody (0.5 µg/mL) for 4 hours.

Results: PE was associated with higher blood pressure (117 ± 2 vs 107 ± 2 mmHg; p < 0.01), plasma MBG levels (1.54 ± 0.34 vs 0.49 ± 0.11 nmol/L; p < 0.01), protein excretion (26 vs 12 mg/24 hours), sFlt-1 (4-fold), decrease in Fli1 (7-fold) and increase in collagen-1 in aorta (4-fold) vs. control rats (all p < 0.01). In 12 rats was treated with polyclonal anti-MBG-4 antibody blood pressure dropped (93 ± 3 mmHg) and Fli1 was decreased much less (2-fold; p < 0.01 vs nontreated rats).

Conclusion: These results demonstrate that in experimental PE elevated MBG level is implicated in umbilical fibrosis via suppression of Fli1. Supported by Russian Scientific Foundation grant № 18-15-00222.

© 2019 Association for Research into Arterial Structure and Physiology. Publishing services by Atlantis Press International B.V. This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).